Prof Simon van Belle speaks about the CHOICE study investigating the use of Aranesp (darbepoetin alfa) to treat cancer patients with chemotherapy-induced anaemia. Prof van Belle reports that this drug has successfully increased haemoglobin levels in over 60% of patients, stresses the importance of starting treatment at the correct stage and explains how the CHOICE trial has clarified when treatment should be stopped. Prof van Belle discusses the frequency that emesis is under treated with antiemetic and how this can be prevented by following good practice guidelines